title: Takotsubo cardiomyopathy after systemic consolidation therapy with high-dose intravenous cytarabine in a patient with acute myeloid leukemia.
abstract: BACKGROUND
  Takotsubo cardiomyopathy (TC) is characterized by the abrupt onset of cardiac dysfunction, with transient apical and midventricular hypo-/akinesia with a compensatory hypercontractility of the remaining segments. The clinical presentation appears to be similar to acute myocardial infarction (AMI). However, the myocardial dysfunction is reversible.
  
  
  METHODS
  We report on the case of a 58-year-old man with acute myeloid leukemia (AML) who was admitted to our hospital to receive the second course of consolidation chemotherapy with intravenous cytarabine. Subsequently, the patient developed severe dyspnea at rest, with cardiogenic shock after the central venous catheter was removed. Echocardiography revealed severe dyskinesia of the mid and apical portions of both ventricles, accompanied by a highly reduced left ventricular function (LVF). 5 months later, 12-lead electrocardiography (ECG) did not show any evidence of repolar-ization disorders and echocardiographic evaluation revealed a normal LVF. We suppose that the underlying mechanism was TC.
  
  
  CONCLUSIONS
  TC can occur in patients with AML under systemic chemotherapy, which possibly represents a triggering factor for TC development. Cardiogenic shock is a serious life-threatening complication of TC. Nevertheless, the prognosis of TC is favorable and a complete recovery of the LVF is possible.
authors.affiliation: First Department of Medicine, Faculty of Medicine Mannheim, University Medical Center Mannheim (UMM), University of Heidelberg, Mannheim, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Baumann
authors.forename: Aydin
authors.initials: A
authors.lastname: Huseynov
authors.forename: Diana
authors.initials: D
authors.lastname: Goranova
authors.forename: Melanie
authors.initials: M
authors.lastname: Faust
authors.forename: Michael
authors.initials: M
authors.lastname: Behnes
authors.forename: Florian
authors.initials: F
authors.lastname: Nolte
authors.forename: Daniela
authors.initials: D
authors.lastname: Heidenreich
authors.forename: Wolf-Karsten
authors.initials: WK
authors.lastname: Hofmann
authors.forename: Martin
authors.initials: M
authors.lastname: Borggrefe
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Akin
authors.forename: Stefan
authors.initials: S
authors.lastname: Klein
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D060830:Consolidation Chemotherapy / Q000009:adverse effects*; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D007275:Injections, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D054549:Takotsubo Cardiomyopathy / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine